Suppr超能文献

辐射通过激活 NF-κB/Icam1 信号增强 EGFR 靶向 CAR-T 细胞对三阴性乳腺癌的疗效。

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.

机构信息

State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.

State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.

出版信息

Mol Ther. 2022 Nov 2;30(11):3379-3393. doi: 10.1016/j.ymthe.2022.07.021. Epub 2022 Aug 4.

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, with limited treatment options. Epidermal growth factor receptor (EGFR) is reported to be expressed in 50%-75% of TNBC patients, making it a promising target for cancer treatment. Here we show that EGFR-targeted chimeric antigen receptor (CAR) T cell therapy combined with radiotherapy provides enhanced antitumor efficacy in immunocompetent and immunodeficient orthotopic TNBC mice. Intriguingly, this combination therapy resulted in a substantial increase in the number of tumor-infiltrating CAR-T cells. The efficacy of this combination was independent of tumor radiosensitivity and lymphodepleting preconditioning. Cytokine profiling showed that this combination did not increase the risk of cytokine release syndrome (CRS). RNA sequencing (RNA-seq) analysis revealed that EGFR-targeting CAR-T therapy combined with radiotherapy increased the infiltration of CD8 T and natural killer (NK) cells into tumors. Mechanistically, radiation significantly increased Icam1 expression on TNBC cells via activating nuclear factor κB (NF-κB) signaling, thereby promoting CAR-T cell infiltration and killing. These results suggest that CAR-T therapy combined with radiotherapy may be a promising strategy for TNBC treatment.

摘要

三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌亚型,治疗选择有限。据报道,表皮生长因子受体(EGFR)在 50%-75%的 TNBC 患者中表达,使其成为癌症治疗的有前途的靶点。在这里,我们表明 EGFR 靶向嵌合抗原受体(CAR)T 细胞疗法联合放射治疗在免疫功能正常和免疫缺陷的原位 TNBC 小鼠中提供了增强的抗肿瘤疗效。有趣的是,这种联合治疗导致肿瘤浸润的 CAR-T 细胞数量大量增加。这种联合治疗的疗效与肿瘤放射敏感性和淋巴耗竭预处理无关。细胞因子分析表明,这种联合治疗不会增加细胞因子释放综合征(CRS)的风险。RNA 测序(RNA-seq)分析显示,EGFR 靶向 CAR-T 疗法联合放射治疗增加了 CD8 T 和自然杀伤(NK)细胞浸润肿瘤。从机制上讲,辐射通过激活核因子κB(NF-κB)信号显著增加 TNBC 细胞上的 Icam1 表达,从而促进 CAR-T 细胞浸润和杀伤。这些结果表明,CAR-T 疗法联合放射治疗可能是治疗 TNBC 的一种有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d289/9637637/390404e72484/fx1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验